United Therapeutics (BSP:U2TH34) Other Long-Term Liabilities: R$1,086 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:U2TH34 United Therapeutics Corp BSP:U2TH34
87 GF Score
Price R$129.50
GF Value R$107.31
! 3 Warning Signs
View Full Analysis

What is United Therapeutics Other Long-Term Liabilities?

United Therapeutics BSP:U2TH34 87 Other Long-Term Liabilities is R$1,086 Mil as of Jun. 2026. GuruFocus rates BSP:U2TH34 with a GF Score™ of 87/100 and a GF Value™ of R$107.31. The stock has 3 warning signs investors should review.

United Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2026 was R$1,086 Mil.

United Therapeutics's quarterly other long-term liabilities declined from Dec. 2025 (R$1,218 Mil) to Mar. 2026 (R$1,119 Mil) and declined from Mar. 2026 (R$1,119 Mil) to Jun. 2026 (R$1,086 Mil).

United Therapeutics's annual other long-term liabilities increased from Dec. 2023 (R$381 Mil) to Dec. 2024 (R$1,110 Mil) and increased from Dec. 2024 (R$1,110 Mil) to Dec. 2025 (R$1,218 Mil).

United Therapeutics Other Long-Term Liabilities Related Terms

United Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Other Long-Term Liabilities Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 592.63 548.67 381.21 1,109.77 1,217.71

United Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,149.65 1,150.90 1,217.71 1,119.14 1,086.31
BSP:U2TH34
87GF Score
United Therapeutics Corp BSP:U2TH34
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of R$1,086 Mil mean?
United Therapeutics (BSP:U2TH34) has a Other Long-Term Liabilities of R$1,086 Mil as of Jun. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Other Long-Term Liabilities too high?
United Therapeutics' current Other Long-Term Liabilities is R$1,086 Mil. Overall, United Therapeutics has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Other Long-Term Liabilities compare to VTRS and NBIX?
United Therapeutics' Other Long-Term Liabilities of R$1,086 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on United Therapeutics and its competitors. United Therapeutics's current Other Long-Term Liabilities is R$1,086 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
United Therapeutics (BSP:U2TH34) has a current Other Long-Term Liabilities of R$1,086 Mil. The stock's GF Value™ is R$107.31, compared to a current price of R$129.50 — trading 20.7% above its estimated fair value. The current Other Long-Term Liabilities is R$1,086 Mil. United Therapeutics' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For United Therapeutics (BSP:U2TH34), the current Other Long-Term Liabilities is R$1,086 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (BSP:U2TH34) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of R$129.50 is trading 20.7% above its estimated GF Value™ of R$107.31.

Key valuation signals for BSP:U2TH34:

  • Other Long-Term Liabilities: R$1,086 Mil
  • GF Value™: R$107.31 vs. price of R$129.50 (20.7% above fair value)
  • GF Score™: 87/100 with 3 warning signs

No single metric tells the full story. See the BSP:U2TH34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

United Therapeutics Business Description

Other Exchanges UTHR:USAUTH:Germany
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
87GF Score

Get the complete analysis for BSP:U2TH34

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$129.50
Price
R$107.31
GF Value